Last reviewed · How we verify
NCT05658536
The COPE Study: Pilot Intervention to Improve Symptom Self-management and Coping in Adults With Post COVID-19
NA trial testing 6-Week Self-Management Group in Post COVID-19 Condition in 51 participants. Completed in 30 January 2024.
30 January 2024
Quick facts
| Lead sponsor | University of Washington |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 51 |
| Start date | 18 January 2023 |
| Primary completion | 30 January 2024 |
| Estimated completion | 30 January 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 6-Week Self-Management Group
Conditions studied
- Post COVID-19 Condition — all drugs for Post COVID-19 Condition →
- Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
Sponsor
University of Washington
Who can join
18 and older, any sex, with Post COVID-19 Condition or Post-COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This project is a randomized controlled pilot trial using mixed methods to examine the feasibility, acceptability, and initial effects of a telemedicine group-based intervention designed to improve symptom management and coping in adults with Post-COVID.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
A pilot randomized controlled trial of a telemedicine psychosocial intervention to improve symptom management in adults with long COVID: the COPE study protocol.
Knowles LM, Grewal M, Drever SA, Hoffman JM, et al · · 2024 · cited 1× · PMID 38886814 · DOI 10.1186/s40814-024-01515-2 -
A pragmatic randomized controlled trial of a telemedicine self-management intervention for adults with long COVID: The COPE study protocol
Knowles LM, Grewal M, Drever S, Hoffman J, et al · · 2024 · DOI 10.21203/rs.3.rs-3684980/v1
Verify or expand the search:
- PubMed search for NCT05658536
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Post COVID-19 Condition
Currently open trials in the same condition.
- NCT07110714 — Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients · NA · recruiting
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06766825 — Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC) · Phase 2 · recruiting
- NCT05946512 — MR-spectroscopy in Post-covid Condition Prior to and Following a Yoga Breathing Intervention · NA · recruiting
- NCT05890534 — Pycnogenol® in Post-COVID-19 Condition · Phase 3 · active not recruiting
Other University of Washington trials
Trials by the same sponsor.
- NCT07430852 — Inherited and Environmental Risks Acting on Body Weight · NA · not yet recruiting
- NCT07466498 — Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Canc · Phase 2 · not yet recruiting
- NCT06422299 — Developing and Testing an Online Intervention for Alcohol and Cannabis Misuse and Healthy Relationship Skills Among Youn · NA · not yet recruiting
- NCT07322341 — SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer · Phase 2 · not yet recruiting
- NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05658536 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Washington
- Last refreshed: 29 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05658536.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing